Assessment of Circulating Tumor Cells and microRNAs in Patients With Metastatic Non-cutaneous Melanoma
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 35
- 试验地点
- 1
- 主要终点
- Melanoma circulating tumor cell (CTC) count (number of CTC/ml)
研究概览
简要总结
the study aims to implement new approaches for the identification of circulating tumor cells and circulating microRNAs, which aim to silence the expression of genes and thus prevent the production of proteins in patients with advanced melanoma (uval, mucosal, of unknown origin). It also aims to verify whether their expression can be related to the prognosis of the disease and the response to treatments.
详细描述
Here we propose a study to identify a technique for the isolation of circulating tumor cells (CTCs) from blood samples of patients with diagnosis of metastatic melanoma (uveal, mucosal, from primary unknown) to identify a potential role of CTCs and to study the role for circulating microRNAs (miRNAs) in the management of metastatic UM, MM and MUP.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of UM, MM or MUP
- •Diagnosis of metastatic disease
- •Age ≥ 18 years, at the time of the tissue collection
排除标准
- •Personal medical history of concomitant other cancer
结局指标
主要结局
Melanoma circulating tumor cell (CTC) count (number of CTC/ml)
时间窗: At enrollment and at every scheduled follow-up visits throughtout the study (24 months)
Evaluate CTCs count (number/ml) in patients with metastatic UM, MM and MUP
Circulating microRNAs (copies/ml)
时间窗: At enrollment and at every scheduled follow-up visits throughtout the study (24 months)
Evaluate circulating microRNAs expression (copies/ul) in patients with metastatic UM, MM and MUP
次要结局
- Overall Survival (OS)(Throughtout the study duration (24 months) for a minumum of 6 months for each patient)
- To correlate the count of CTC and the expression of circulating microRNAs with patients' prognosis in order to discover liquid biomarkers for prognosis of UM, MM and MUP(Throughtout the study duration (24 months) for a minumum of 6 months for each patient)